Abstract
Summary Oropouche virus (OROV), initially detected in Trinidad and Tobago in 1955, has been historically confined to the Amazon Basin. However, since late 2022, OROV has been reported in northern Brazil as well as urban centers in Bolivia, Colombia, Cuba, and Peru. Herein, we describe the generation of 133 new publicly available full genomes. We show how the virus evolved via genome component reassortment and how it rapidly spread across multiple states in Brazil, causing the largest outbreak ever recorded outside the Amazon basin, including the first detected deaths. This work highlights the need for heightened epidemiological and genomic surveillance and the implementation of adequate measures in order to mitigate transmission and the impacts on the population.
Background Oropouche virus was first identified in 1955 in Trinidad and Tobago and later found in Brazil in 1960. Historically, it has been reported to have caused around 30 outbreaks, mostly within the Amazon Basin, where it circulates among forest animals, but also in urban areas where it is known to be transmitted by the midge Culicoides paraensis. Recently, Brazil has seen a surge in cases, with more than 7000 reported by mid-2024 alone.
Methods In a collaboration with Central Public Health Laboratories across Brazilian regions, we integrated epidemiological metadata with genomic analyses of recently sampled cases. This initiative resulted in the generation of 133 whole genome sequences from the three genomic segments (L, M, and S) of the virus, including the first genomes obtained from regions outside the Amazon and from the first ever recorded fatal cases.
Findings All of the 2024 genomes form a monophyletic group in the phylogenetic tree with sequences from the Amazon Basin sampled since 2022. Our analyses revealed a rapid north-to-south viral movement from the Amazon Basin into historically non-endemic regions. We identified 21 reassortment events, although it remains unclear if genomic evolution of the virus enabled the virus to adapt to local ecological conditions and evolve new phenotypes of public health importance.
Interpretation Both the recent rapid spatial expansion and the first reported fatalities associated with Oropouche (and other outcomes under investigation) underscore the importance of enhancing surveillance for this evolving pathogen across the Region. Without any obvious changes in the human population over the past 2 years, it is possible that viral adaptation, deforestation and recent climate change, either alone or in combination, have propelled Oropouche virus beyond the Amazon Basin.
Evidence before this study Before this study, Oropouche virus (OROV) was known to cause periodic outbreaks primarily within the Amazon Basin. Initially identified in Trinidad and Tobago in 1955, the virus had been responsible for approximately 30 outbreaks in Latin America, mostly confined to the Amazon region. The virus typically circulates among forest animals and is transmitted to humans by the bite of the midge Culicoides paraensis. There has been an historical dearth of available genomic data, and so far the spread beyond the Amazon Basin has not been well-documented.
Added value of this study This study provides a timely and comprehensive analysis of epidemiological and genomic data of Oropouche virus from regions outside the Amazon Basin. By generating 133 whole genome sequences from various regions across Brazil, this study reveals the movement of OROV over the past few years across Brazil, with a north-south spatial movement from regions of historic endemicity to regions with clear epidemic potential. We identify 21 reassortment events, with the possible occurrence of virus adaptation to new environments. We also report the first fatal cases of Oropouche virus infection in patients without underlying relevant comorbidities, underscoring the public health risk of future outbreaks and the need for increased awareness and surveillance.
Implications of all the available evidence The rapid spread of Oropouche virus beyond the Amazon Basin into regions of Brazil more than 3500 Km distant, coupled with the identification of genome reassortment events, raises the possibility that the virus is adapting to the new environments of its increasing spatial landscape. This evolution could lead to the emergence of new viral phenotypes, with potential changes at various levels, from vector efficiency to disease outcome, raising the challenge of managing future outbreaks. This underscores the critical need for enhanced surveillance systems at national and continental levels, particularly in urban centers that appear to have been hit hard during the spatial expansion, to detect and respond to Oropouche virus outbreaks promptly.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN), the CRP ICGEB RESEARCH GRANT 2020 Project CRP/BRA20-03, Contract CRP/20/03, and the Rede Unificada de Analises Integradas de Arbovirus de Minas Gerais (REDE UAI ARBOMG), financed by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), grant number RED0023423. M. Giovanetti's funding is provided by PON "Ricerca e Innovazione'' 2014, 2020. T.E.R.A. is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) under the process number 153597/2024-0. F.C.M.I. is supported by FAPEMIG under process number BIP-00123-23. The authors would also like to acknowledge the Global Consortium to Identify and Control Epidemics CLIMADE (https://climade.health/).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project was reviewed and approved by the Ethical Committee of the Federal University of Minas Gerais (CAAE: 32912820.6.1001.5149). The availability of the samples for research purposes during outbreaks of national concern is allowed by the terms of the 510/2016 Resolution of the National Ethical Committee for Research (CONEP - Comissao Nacional de Etica em Pesquisa, Ministerio da Saude) of the Brazilian Ministry of Health (BrMoH), that authorize, without the necessity of an informed consent, the use of clinical samples collected in the Brazilian Central Public Health Laboratories to accelerate knowledge building and contribute to surveillance and outbreak response. The samples processed in this study were obtained anonymously from material collected during routine arboviral diagnosis in Brazilian public health laboratories within the BrMoH network.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
In the current manuscript version, we have made slight changes to the text and figures.
Data Availability
NA
